/**
 * Menopausia | Menopause - Comprehensive Educational Content
 *
 * Covers perimenopause, menopause, postmenopause, and hormone therapy
 * from basic health literacy through evidence-based clinical protocols.
 * Spanish-first with English translations.
 */

import { EducationalContent } from '../types';

export const menopausiaMenopause: EducationalContent = {
  id: 'womens-health-menopausia-menopause',
  type: 'process',
  name: 'Menopausia | Menopause',
  nameEs: 'Menopausia',
  alternateNames: [
    'Climaterio | Climacteric',
    'Transici\u00f3n menop\u00e1usica | Menopausal transition',
    'Perimenopausia | Perimenopause',
  ],

  levels: {
    1: {
      level: 1,
      summary:
        'La menopausia es cuando la mujer deja de tener la regla de forma permanente, generalmente alrededor de los 50 a\u00f1os, y es una etapa natural de la vida. | Menopause is when a woman permanently stops having her period, usually around age 50, and is a natural stage of life.',
      explanation: `## \u00bfQu\u00e9 es la menopausia? | What is menopause?

La menopausia es una etapa natural en la vida de toda mujer. Ocurre cuando los ovarios dejan de producir \u00f3vulos y las hormonas bajan. Se confirma cuando pasan **12 meses seguidos sin la regla**. | Menopause is a natural stage in every woman\u2019s life. It happens when the ovaries stop producing eggs and hormones decrease. It is confirmed after **12 consecutive months without a period**.

### Las tres etapas | The Three Stages

1. **Perimenopausia** \u2013 Los a\u00f1os antes de la menopausia (puede durar 4-8 a\u00f1os) | The years before menopause (can last 4-8 years)
   - La regla se vuelve irregular | Periods become irregular
   - Los s\u00edntomas empiezan | Symptoms begin

2. **Menopausia** \u2013 Cuando has pasado 12 meses sin regla | When you\u2019ve gone 12 months without a period
   - Edad promedio: 51 a\u00f1os | Average age: 51 years

3. **Postmenopausia** \u2013 Los a\u00f1os despu\u00e9s de la menopausia | The years after menopause

### S\u00edntomas comunes | Common Symptoms

- **Bochornos (sofocos)**: Sensaci\u00f3n repentina de calor en cara y pecho | **Hot flashes**: Sudden feeling of heat in face and chest
- **Sudores nocturnos**: Despertar empapada de sudor | **Night sweats**: Waking up drenched in sweat
- **Cambios de humor**: Irritabilidad, tristeza, ansiedad | **Mood changes**: Irritability, sadness, anxiety
- **Dificultad para dormir** | **Difficulty sleeping**
- **Sequedad vaginal** | **Vaginal dryness**
- **Cambios en la piel y el cabello** | **Changes in skin and hair**
- **Aumento de peso** | **Weight gain**

### Qu\u00e9 puedes hacer | What you can do

- **Ejercicio regular** \u2013 ayuda con el \u00e1nimo, huesos y peso | **Regular exercise** \u2013 helps with mood, bones, and weight
- **Comer bien** \u2013 calcio y vitamina D para los huesos | **Eat well** \u2013 calcium and vitamin D for bones
- **Vestirse en capas** \u2013 para los bochornos | **Dress in layers** \u2013 for hot flashes
- **Hablar con tu doctor** \u2013 hay tratamientos que pueden ayudar | **Talk to your doctor** \u2013 there are treatments that can help
- **Mantener relaciones sociales** \u2013 el apoyo emocional es importante | **Maintain social connections** \u2013 emotional support is important

### Cu\u00e1ndo ir al doctor | When to see your doctor

- Sangrado vaginal despu\u00e9s de la menopausia (SIEMPRE) | Vaginal bleeding after menopause (ALWAYS)
- Bochornos que afectan tu vida diaria | Hot flashes affecting your daily life
- S\u00edntomas de depresi\u00f3n | Symptoms of depression
- Dolor al tener relaciones sexuales | Pain during sexual intercourse`,
      keyTerms: [
        {
          term: 'Menopausia | Menopause',
          definition:
            'Cuando la mujer deja de tener la regla permanentemente (12 meses sin regla). | When a woman permanently stops having her period (12 months without a period).',
        },
        {
          term: 'Perimenopausia | Perimenopause',
          definition:
            'Los a\u00f1os de transici\u00f3n antes de la menopausia cuando los s\u00edntomas comienzan. | The years of transition before menopause when symptoms begin.',
        },
        {
          term: 'Bochornos / Sofocos | Hot flashes',
          definition:
            'Sensaci\u00f3n s\u00fabita de calor intenso, especialmente en cara y pecho. | Sudden sensation of intense heat, especially in face and chest.',
        },
        {
          term: 'Hormonas | Hormones',
          definition:
            'Sustancias qu\u00edmicas del cuerpo que controlan muchas funciones, incluyendo la regla. | Chemical substances in the body that control many functions, including the period.',
        },
      ],
      analogies: [
        'La menopausia es como la jubilaci\u00f3n de los ovarios \u2013 despu\u00e9s de a\u00f1os de trabajo, descansan permanentemente. | Menopause is like retirement for the ovaries \u2013 after years of work, they permanently rest.',
        'Los bochornos son como cuando el termostato de tu cuerpo se desajusta temporalmente. | Hot flashes are like when your body\u2019s thermostat temporarily malfunctions.',
      ],
      examples: [
        'Carmen tiene 48 a\u00f1os y su regla ha sido irregular por 2 a\u00f1os. Tiene bochornos y dificultad para dormir. Su doctor le explica que est\u00e1 en la perimenopausia. | Carmen is 48 and her periods have been irregular for 2 years. She has hot flashes and trouble sleeping. Her doctor explains she is in perimenopause.',
      ],
      patientCounselingPoints: [
        'La menopausia es natural \u2013 no es una enfermedad. | Menopause is natural \u2013 it is not a disease.',
        'El sangrado despu\u00e9s de la menopausia SIEMPRE necesita evaluaci\u00f3n m\u00e9dica. | Bleeding after menopause ALWAYS needs medical evaluation.',
        'Hay tratamientos efectivos para los s\u00edntomas \u2013 no tienes que sufrir en silencio. | There are effective treatments for symptoms \u2013 you don\u2019t have to suffer in silence.',
      ],
    },

    2: {
      level: 2,
      summary:
        'La transici\u00f3n menop\u00e1usica est\u00e1 marcada por la disminuci\u00f3n de estr\u00f3geno ov\u00e1rico, causando s\u00edntomas vasomotores, genitourinarios y metab\u00f3licos; las opciones de tratamiento incluyen terapia hormonal, terapias no hormonales y cambios en el estilo de vida. | The menopausal transition is marked by declining ovarian estrogen, causing vasomotor, genitourinary, and metabolic symptoms; treatment options include hormone therapy, non-hormonal therapies, and lifestyle changes.',
      explanation: `## La transici\u00f3n hormonal | The Hormonal Transition

### Qu\u00e9 pasa con las hormonas | What happens with hormones

| Hormona | Hormone | Cambio | Change |
|---------|---------|--------|--------|
| Estr\u00f3geno | Estrogen | Disminuye significativamente | Decreases significantly |
| Progesterona | Progesterone | Disminuye (ciclos anovulatorios) | Decreases (anovulatory cycles) |
| FSH | FSH | Aumenta mucho (>25-30 mUI/mL) | Increases greatly (>25-30 mIU/mL) |
| Testosterona | Testosterone | Disminuye gradualmente | Gradually decreases |

### Etapas STRAW+10 simplificadas | Simplified STRAW+10 Stages
- **Transici\u00f3n temprana**: Ciclos con variaci\u00f3n >7 d\u00edas en duraci\u00f3n | **Early transition**: Cycles with >7-day variation in length
- **Transici\u00f3n tard\u00eda**: Periodos de amenorrea >60 d\u00edas | **Late transition**: Periods of amenorrhea >60 days
- **Postmenopausia temprana**: 0-6 a\u00f1os despu\u00e9s del \u00faltimo periodo | **Early postmenopause**: 0-6 years after last period
- **Postmenopausia tard\u00eda**: >6 a\u00f1os despu\u00e9s | **Late postmenopause**: >6 years after

## Consecuencias de la deficiencia de estr\u00f3geno | Consequences of Estrogen Deficiency

### S\u00edntomas vasomotores | Vasomotor Symptoms
- Bochornos: afectan al 75% de las mujeres | Hot flashes: affect 75% of women
- Duran en promedio 7.4 a\u00f1os (estudio SWAN) | Last an average of 7.4 years (SWAN study)
- M\u00e1s severos en mujeres afroamericanas e hispanas | More severe in African American and Hispanic women
- Mecanismo: Disfunci\u00f3n del centro termorregulador hipotal\u00e1mico | Mechanism: Hypothalamic thermoregulatory center dysfunction

### S\u00edndrome genitourinario de la menopausia (SGM) | Genitourinary Syndrome of Menopause (GSM)
- Sequedad y atrofia vaginal | Vaginal dryness and atrophy
- Dispareunia (dolor con relaciones sexuales) | Dyspareunia (pain during intercourse)
- Urgencia y frecuencia urinaria | Urinary urgency and frequency
- Infecciones urinarias recurrentes | Recurrent urinary tract infections
- **Importante**: No mejora sin tratamiento, empeora con el tiempo | **Important**: Does not improve without treatment, worsens over time

### Efectos en los huesos | Effects on Bones
- P\u00e9rdida acelerada de densidad \u00f3sea los primeros 5-7 a\u00f1os | Accelerated bone density loss in the first 5-7 years
- Aumento del riesgo de osteoporosis y fracturas | Increased risk of osteoporosis and fractures
- Importancia de calcio (1200 mg/d\u00eda), vitamina D (800-1000 UI/d\u00eda) y ejercicio de resistencia | Importance of calcium (1200 mg/day), vitamin D (800-1000 IU/day), and resistance exercise

### Efectos cardiovasculares | Cardiovascular Effects
- P\u00e9rdida del efecto cardioprotector del estr\u00f3geno | Loss of estrogen\u2019s cardioprotective effect
- Aumento de LDL, disminuci\u00f3n de HDL | LDL increases, HDL decreases
- Aumento de riesgo cardiovascular | Increased cardiovascular risk

## Opciones de tratamiento | Treatment Options

### Terapia hormonal (TH) | Hormone Therapy (HT)
- **Mejor opci\u00f3n para bochornos severos** | **Best option for severe hot flashes**
- Estr\u00f3geno sist\u00e9mico + progest\u00e1geno (si tiene \u00fatero) | Systemic estrogen + progestogen (if has uterus)
- Estr\u00f3geno solo si no tiene \u00fatero (post-histerectom\u00eda) | Estrogen only if no uterus (post-hysterectomy)
- Iniciar antes de los 60 a\u00f1os o dentro de 10 a\u00f1os de la menopausia | Start before age 60 or within 10 years of menopause

### Terapias no hormonales | Non-Hormonal Therapies
- **Fezolinetant** (antagonista de neuroquinina B): aprobado FDA 2023 para bochornos | **Fezolinetant** (neurokinin B antagonist): FDA-approved 2023 for hot flashes
- **ISRS/IRSN**: paroxetina, venlafaxina, desvenlafaxina | **SSRIs/SNRIs**: paroxetine, venlafaxine, desvenlafaxine
- **Gabapentina**: especialmente \u00fatil para sudores nocturnos | **Gabapentin**: especially useful for night sweats
- **Estr\u00f3geno vaginal local**: para SGM, absorci\u00f3n sist\u00e9mica m\u00ednima | **Local vaginal estrogen**: for GSM, minimal systemic absorption

### Cambios en estilo de vida | Lifestyle Changes
- Ejercicio aer\u00f3bico y de resistencia 150 min/semana | Aerobic and resistance exercise 150 min/week
- Mantener peso saludable | Maintain healthy weight
- Limitar cafe\u00edna, alcohol, comidas picantes (pueden desencadenar bochornos) | Limit caffeine, alcohol, spicy foods (can trigger hot flashes)
- T\u00e9cnicas de relajaci\u00f3n y mindfulness | Relaxation techniques and mindfulness`,
      keyTerms: [
        {
          term: 'S\u00edntomas vasomotores | Vasomotor Symptoms',
          definition:
            'Bochornos y sudores nocturnos causados por disfunci\u00f3n del centro termorregulador. | Hot flashes and night sweats caused by thermoregulatory center dysfunction.',
        },
        {
          term: 'SGM (S\u00edndrome genitourinario de la menopausia) | GSM (Genitourinary Syndrome of Menopause)',
          definition:
            'Conjunto de s\u00edntomas vaginales y urinarios causados por la deficiencia de estr\u00f3geno. | Collection of vaginal and urinary symptoms caused by estrogen deficiency.',
        },
        {
          term: 'Terapia hormonal (TH) | Hormone Therapy (HT)',
          definition:
            'Tratamiento con estr\u00f3geno (con o sin progest\u00e1geno) para s\u00edntomas menop\u00e1usicos. | Treatment with estrogen (with or without progestogen) for menopausal symptoms.',
        },
        {
          term: 'Fezolinetant',
          definition:
            'Medicamento no hormonal aprobado en 2023 que bloquea la neuroquinina B para tratar bochornos. | Non-hormonal medication approved in 2023 that blocks neurokinin B to treat hot flashes.',
        },
        {
          term: 'STRAW+10',
          definition:
            'Sistema de estadificaci\u00f3n del envejecimiento reproductivo de la mujer. | Stages of Reproductive Aging Workshop classification system.',
        },
      ],
      analogies: [
        'El centro termorregulador en la menopausia es como un termostato con la zona de confort muy estrecha \u2013 cualquier peque\u00f1o cambio de temperatura desencadena una respuesta exagerada (el bochorno). | The thermoregulatory center in menopause is like a thermostat with a very narrow comfort zone \u2013 any small temperature change triggers an exaggerated response (the hot flash).',
      ],
      examples: [
        'Patricia, de 55 a\u00f1os, tiene bochornos tan severos que la despiertan 5 veces por noche. Su ginec\u00f3logo le prescribe terapia hormonal combinada despu\u00e9s de evaluar sus riesgos. | Patricia, 55, has hot flashes so severe they wake her 5 times a night. Her gynecologist prescribes combined hormone therapy after evaluating her risks.',
      ],
    },

    3: {
      level: 3,
      summary:
        'La fisiopatolog\u00eda de la menopausia involucra el agotamiento folicular ov\u00e1rico con p\u00e9rdida de inhibina y estradiol, causando elevaci\u00f3n de FSH; la terapia hormonal tiene un perfil beneficio-riesgo favorable seg\u00fan la "hip\u00f3tesis de la ventana de oportunidad" cuando se inicia en la postmenopausia temprana. | The pathophysiology of menopause involves ovarian follicular depletion with loss of inhibin and estradiol, causing FSH elevation; hormone therapy has a favorable benefit-risk profile per the "window of opportunity hypothesis" when initiated in early postmenopause.',
      explanation: `## Fisiopatolog\u00eda del agotamiento ov\u00e1rico | Pathophysiology of Ovarian Depletion

### Cronolog\u00eda del agotamiento folicular | Follicular Depletion Timeline
- Al nacer: ~1-2 millones de fol\u00edculos primordiales | At birth: ~1-2 million primordial follicles
- Pubertad: ~300,000-400,000 fol\u00edculos | Puberty: ~300,000-400,000 follicles
- 37 a\u00f1os: Aceleraci\u00f3n de la atresia (umbral cr\u00edtico ~25,000 fol\u00edculos) | Age 37: Atresia acceleration (critical threshold ~25,000 follicles)
- Menopausia: < 1,000 fol\u00edculos | Menopause: < 1,000 follicles

### Cascada endocrina | Endocrine Cascade
1. Disminuci\u00f3n de fol\u00edculos funcionales | Decrease in functional follicles
2. \u2193 Inhibina B (p\u00e9rdida de retroalimentaci\u00f3n selectiva sobre FSH) | \u2193 Inhibin B (loss of selective FSH feedback)
3. \u2191 FSH (primer marcador de envejecimiento ov\u00e1rico) | \u2191 FSH (first marker of ovarian aging)
4. \u2193 Estradiol (progresivamente) | \u2193 Estradiol (progressively)
5. Ciclos anovulatorios con \u2193 progesterona | Anovulatory cycles with \u2193 progesterone
6. Fuente principal de estr\u00f3geno postmenop\u00e1usico: conversi\u00f3n perif\u00e9rica de androstenediona a estrona (aromatasa en tejido adiposo) | Main source of postmenopausal estrogen: peripheral conversion of androstenedione to estrone (aromatase in adipose tissue)

### Neurofisiolog\u00eda de los bochornos | Neurophysiology of Hot Flashes
- La zona termoneutral hipotal\u00e1mica se estrecha | Hypothalamic thermoneutral zone narrows
- Neuronas KNDy hipertrofiadas en el n\u00facleo infundibular (por p\u00e9rdida de inhibici\u00f3n estrog\u00e9nica) | Hypertrophied KNDy neurons in the infundibular nucleus (due to loss of estrogenic inhibition)
- Neuroquinina B (NKB) desencadena vasodilataci\u00f3n perif\u00e9rica y sudoraci\u00f3n | Neurokinin B (NKB) triggers peripheral vasodilation and sweating
- Explica el mecanismo de acci\u00f3n del fezolinetant (antagonista de receptor NK3) | Explains the mechanism of action of fezolinetant (NK3 receptor antagonist)

## Terapia Hormonal Menop\u00e1usica (THM) | Menopausal Hormone Therapy (MHT)

### Hip\u00f3tesis de la ventana de oportunidad | Window of Opportunity Hypothesis
- Iniciar THM dentro de los **10 a\u00f1os de la menopausia o antes de los 60 a\u00f1os** | Start MHT within **10 years of menopause or before age 60**
- En este periodo: beneficio cardiovascular neto | In this window: net cardiovascular benefit
- Despu\u00e9s de este periodo: posible aumento de riesgo cardiovascular | After this window: possible increased cardiovascular risk
- Evidencia: WHI re-an\u00e1lisis por edad, estudios ELITE y KEEPS | Evidence: WHI age-stratified reanalysis, ELITE and KEEPS studies

### Reg\u00edmenes de THM | MHT Regimens

| Tipo | Type | Indicaci\u00f3n | Indication | R\u00e9gimen | Regimen |
|------|------|-------------|------------|---------|---------|
| EPT c\u00edclica | Cyclic EPT | Perimenopausia | Perimenopause | E continuo + P 12-14 d\u00edas/mes | Continuous E + P 12-14 days/month |
| EPT continua | Continuous EPT | Postmenopausia (>1 a\u00f1o) | Postmenopause (>1 year) | E + P continuos | Continuous E + P |
| ET sola | ET alone | Post-histerectom\u00eda | Post-hysterectomy | E continuo sin P | Continuous E without P |
| Estr\u00f3geno vaginal | Vaginal E | SGM aislado | Isolated GSM | Crema, anillo, o tableta vaginal | Cream, ring, or vaginal tablet |
| Tibolona | Tibolone | Bochornos + libido | Hot flashes + libido | 2.5 mg/d\u00eda VO | 2.5 mg/day PO |

### Formulaciones de estr\u00f3geno | Estrogen Formulations
- **Estradiol transde\u0301rmico** (parche 0.025-0.1 mg): Menor riesgo tromboemb\u00f3lico que la v\u00eda oral | **Transdermal estradiol** (patch 0.025-0.1 mg): Lower thromboembolic risk than oral
- **Estradiol oral** 0.5-2 mg: Efecto de primer paso hep\u00e1tico | **Oral estradiol** 0.5-2 mg: Hepatic first-pass effect
- **Estr\u00f3genos conjugados equinos (ECE)** 0.3-0.625 mg: Formulaci\u00f3n del WHI | **Conjugated equine estrogens (CEE)** 0.3-0.625 mg: WHI formulation

### Contraindicaciones de THM | MHT Contraindications
- C\u00e1ncer de mama actual o antecedente | Current or history of breast cancer
- Enfermedad coronaria o ACV | Coronary artery disease or stroke
- Tromboembolismo venoso activo | Active venous thromboembolism
- Sangrado vaginal no diagnosticado | Undiagnosed vaginal bleeding
- Enfermedad hep\u00e1tica activa | Active liver disease

## Menopausia prematura e insuficiencia ov\u00e1rica primaria (IOP) | Premature Menopause and Primary Ovarian Insufficiency (POI)

- Definici\u00f3n: Menopausia antes de los 40 a\u00f1os | Definition: Menopause before age 40
- Afecta al 1% de las mujeres | Affects 1% of women
- Causas: autoinmune (m\u00e1s com\u00fan), gen\u00e9tica (Turner, premutaci\u00f3n FMR1), iatrog\u00e9nica (cirug\u00eda, quimioterapia, radiaci\u00f3n) | Causes: autoimmune (most common), genetic (Turner, FMR1 premutation), iatrogenic (surgery, chemotherapy, radiation)
- THM recomendada hasta la edad promedio de menopausia natural (51 a\u00f1os) | MHT recommended until average age of natural menopause (51 years)
- Riesgo aumentado de osteoporosis, enfermedad cardiovascular, deterioro cognitivo | Increased risk of osteoporosis, cardiovascular disease, cognitive decline`,
      keyTerms: [
        {
          term: 'Inhibina B | Inhibin B',
          definition:
            'Hormona producida por c\u00e9lulas de la granulosa que suprime selectivamente FSH; su disminuci\u00f3n es el primer marcador de envejecimiento ov\u00e1rico. | Hormone produced by granulosa cells that selectively suppresses FSH; its decline is the first marker of ovarian aging.',
        },
        {
          term: 'Ventana de oportunidad | Window of Opportunity',
          definition:
            'Per\u00edodo de los primeros 10 a\u00f1os posmenopausia en que la THM tiene el perfil beneficio-riesgo m\u00e1s favorable. | Period of the first 10 years post-menopause when MHT has the most favorable benefit-risk profile.',
        },
        {
          term: 'Insuficiencia ov\u00e1rica primaria (IOP) | Primary Ovarian Insufficiency (POI)',
          definition:
            'Falla ov\u00e1rica antes de los 40 a\u00f1os con FSH elevada y deficiencia de estr\u00f3geno. | Ovarian failure before age 40 with elevated FSH and estrogen deficiency.',
        },
        {
          term: 'Neuronas KNDy | KNDy Neurons',
          definition:
            'Neuronas hipotal\u00e1micas que median los bochornos a trav\u00e9s de neuroquinina B cuando la inhibici\u00f3n estrog\u00e9nica se pierde. | Hypothalamic neurons that mediate hot flashes through neurokinin B when estrogenic inhibition is lost.',
        },
        {
          term: 'Estrona | Estrone',
          definition:
            'Estr\u00f3geno d\u00e9bil producido por conversi\u00f3n perif\u00e9rica de androstenediona en tejido adiposo; estr\u00f3geno principal en la postmenopausia. | Weak estrogen produced by peripheral conversion of androstenedione in adipose tissue; main estrogen in postmenopause.',
        },
      ],
      analogies: [
        'La ventana de oportunidad para la THM es como plantar un \u00e1rbol: si lo plantas cuando el suelo vascular est\u00e1 sano, crece bien y protege; si lo plantas cuando ya hay da\u00f1o, puede causar m\u00e1s problemas. | The window of opportunity for MHT is like planting a tree: if you plant it when the vascular soil is healthy, it grows well and protects; if you plant it when there\u2019s already damage, it can cause more problems.',
      ],
      examples: [
        'Una mujer de 52 a\u00f1os, 1 a\u00f1o posmenopausia, con bochornos moderados-severos, sin antecedente de c\u00e1ncer de mama ni enfermedad cardiovascular: es candidata ideal para THM dentro de la ventana de oportunidad. | A 52-year-old woman, 1 year postmenopausal, with moderate-severe hot flashes, no history of breast cancer or cardiovascular disease: she is an ideal candidate for MHT within the window of opportunity.',
      ],
    },

    4: {
      level: 4,
      summary:
        'El manejo cl\u00ednico avanzado de la menopausia incluye la interpretaci\u00f3n del estudio WHI en contexto, algoritmos de selecci\u00f3n de THM individualizados por v\u00eda y formulaci\u00f3n, evaluaci\u00f3n de riesgo tromboemb\u00f3lico y mamario, y protocolos de manejo del SGM con terapias locales y sist\u00e9micas. | Advanced clinical management of menopause includes WHI study interpretation in context, individualized MHT selection algorithms by route and formulation, thromboembolic and breast cancer risk assessment, and GSM management protocols with local and systemic therapies.',
      explanation: `## Re-interpretaci\u00f3n del WHI | WHI Reinterpretation

### Hallazgos originales del WHI vs. re-an\u00e1lisis | Original WHI Findings vs. Reanalysis

**Brazo ECE+MPA (mujeres con \u00fatero):** | **CEE+MPA Arm (women with uterus):**
| Resultado | Outcome | Riesgo original | Original risk | Re-an\u00e1lisis 50-59 a | Reanalysis 50-59 y |
|-----------|---------|----------------|--------------|---------------------|---------------------|
| ECV | CAD | HR 1.24 | HR 1.24 | HR 0.88 (NS) | HR 0.88 (NS) |
| ACV | Stroke | HR 1.31 | HR 1.31 | HR 1.10 (NS) | HR 1.10 (NS) |
| TEV | VTE | HR 2.06 | HR 2.06 | HR 1.49 | HR 1.49 |
| C\u00e1ncer de mama | Breast cancer | HR 1.24 | HR 1.24 | HR 1.24 | HR 1.24 |
| C\u00e1ncer colorrectal | Colorectal cancer | HR 0.56 | HR 0.56 | Protector | Protective |
| Fractura de cadera | Hip fracture | HR 0.67 | HR 0.67 | Protector | Protective |

**Brazo ECE sola (post-histerectom\u00eda):** | **CEE-alone Arm (post-hysterectomy):**
- C\u00e1ncer de mama: HR 0.77 (protecci\u00f3n a los 20 a\u00f1os de seguimiento) | Breast cancer: HR 0.77 (protection at 20-year follow-up)
- Mortalidad total: HR 0.87 en menores de 60 a\u00f1os | All-cause mortality: HR 0.87 in women under 60

### Limitaciones del WHI | WHI Limitations
- Edad promedio 63 a\u00f1os (no representa inicio temprano) | Average age 63 (not representative of early initiation)
- Solo ECE orales y MPA (no estradiol transde\u0301rmico ni progesterona micronizada) | Only oral CEE and MPA (not transdermal estradiol or micronized progesterone)
- MPA tiene perfil cardiovascular/mamario menos favorable que progesterona micronizada | MPA has less favorable cardiovascular/breast profile than micronized progesterone

## Algoritmo de prescripci\u00f3n individualizada | Individualized Prescribing Algorithm

### Selecci\u00f3n de v\u00eda de administraci\u00f3n | Route Selection

**Transde\u0301rmica preferida si:** | **Transdermal preferred if:**
- Riesgo tromboemb\u00f3lico (obesidad IMC >30, tabaquismo, migraÃ±a con aura, antecedente TEV) | Thromboembolic risk (obesity BMI >30, smoking, migraine with aura, VTE history)
- Triglic\u00e9ridos elevados | Elevated triglycerides
- Enfermedad hep\u00e1tica o vesicular | Hepatic or gallbladder disease
- Hipertensi\u00f3n | Hypertension

**Selecci\u00f3n de progest\u00e1geno:** | **Progestogen Selection:**
- **Progesterona micronizada** 100-200 mg: Perfil cardiovascular y mamario m\u00e1s favorable (estudio E3N franc\u00e9s) | **Micronized progesterone** 100-200 mg: More favorable cardiovascular and breast profile (French E3N study)
- **DIU-LNG**: Protecci\u00f3n endometrial local sin efectos sist\u00e9micos | **LNG-IUD**: Local endometrial protection without systemic effects
- **Didrogesterona**: Ret\u00f3mero de progesterona con buena tolerabilidad | **Dydrogesterone**: Retro-isomer of progesterone with good tolerability

## Manejo avanzado del SGM | Advanced GSM Management

### Protocolo escalonado | Step-Up Protocol
1. **Hidratantes y lubricantes vaginales** (primera l\u00ednea no hormonal) | **Vaginal moisturizers and lubricants** (first-line non-hormonal)
2. **Estr\u00f3geno vaginal de baja dosis** | **Low-dose vaginal estrogen**
   - Estradiol 10 mcg tableta vaginal 2x/semana | Estradiol 10 mcg vaginal tablet 2x/week
   - Crema de estriol 0.5 mg 2-3x/semana | Estriol cream 0.5 mg 2-3x/week
   - Anillo de estradiol 7.5 mcg/d\u00eda (3 meses) | Estradiol ring 7.5 mcg/day (3 months)
3. **Prasterona (DHEA vaginal)** 6.5 mg/d\u00eda: Alternativa para sequedad y dispareunia | **Prasterone (vaginal DHEA)** 6.5 mg/day: Alternative for dryness and dyspareunia
4. **Ospemifeno** 60 mg/d\u00eda VO: SERM para dispareunia (no en antecedente de TEV) | **Ospemifene** 60 mg/day PO: SERM for dyspareunia (not in VTE history)

### Consideraciones con estr\u00f3geno vaginal | Vaginal Estrogen Considerations
- Absorci\u00f3n sist\u00e9mica m\u00ednima con dosis bajas | Minimal systemic absorption with low doses
- Niveles de estradiol permanecen en rango postmenop\u00e1usico | Estradiol levels remain in postmenopausal range
- ACOG y NAMS: no requiere progest\u00e1geno concomitante a dosis bajas | ACOG and NAMS: does not require concomitant progestogen at low doses
- Puede usarse en sobrevivientes de c\u00e1ncer de mama (discutir con oncolog\u00eda) | Can be used in breast cancer survivors (discuss with oncology)`,
      keyTerms: [
        {
          term: 'WHI (Women\u2019s Health Initiative)',
          definition:
            'Estudio cl\u00ednico aleatorizado que defini\u00f3 riesgos/beneficios de THM; sus conclusiones deben interpretarse con las limitaciones de edad y formulaci\u00f3n. | Randomized clinical trial that defined MHT risks/benefits; conclusions must be interpreted with age and formulation limitations.',
        },
        {
          term: 'Progesterona micronizada | Micronized Progesterone',
          definition:
            'Progesterona bioide\u0301ntica con mejor perfil cardiovascular y mamario que el acetato de medroxiprogesterona (MPA). | Bioidentical progesterone with better cardiovascular and breast profile than medroxyprogesterone acetate (MPA).',
        },
        {
          term: 'Ospemifeno | Ospemifene',
          definition:
            'Modulador selectivo del receptor de estr\u00f3geno (SERM) oral aprobado para dispareunia del SGM. | Selective estrogen receptor modulator (SERM) approved orally for GSM dyspareunia.',
        },
        {
          term: 'Prasterona (DHEA vaginal) | Prasterone (Vaginal DHEA)',
          definition:
            'Precursor androg\u00e9nico intravaginal que se convierte localmente en estr\u00f3geno y testosterona. | Intravaginal androgen precursor that converts locally to estrogen and testosterone.',
        },
        {
          term: 'Estudio E3N',
          definition:
            'Estudio de cohorte franc\u00e9s que demostr\u00f3 que la progesterona micronizada no aumenta el riesgo de c\u00e1ncer de mama a diferencia del MPA. | French cohort study that showed micronized progesterone does not increase breast cancer risk unlike MPA.',
        },
      ],
      clinicalNotes:
        'Prescribir la dosis m\u00e1s baja efectiva por el menor tiempo necesario. Re-evaluar anualmente la necesidad de continuar THM. La v\u00eda transde\u0301rmica con progesterona micronizada tiene el mejor perfil de seguridad. El fezolinetant es la primera alternativa no hormonal con eficacia comparable para bochornos (SKYLIGHT trials). | Prescribe the lowest effective dose for the shortest necessary time. Reassess annually the need to continue MHT. Transdermal route with micronized progesterone has the best safety profile. Fezolinetant is the first non-hormonal alternative with comparable efficacy for hot flashes (SKYLIGHT trials).',
    },

    5: {
      level: 5,
      summary:
        'Protocolos avanzados de manejo menop\u00e1usico incluyen el modelo integrado de riesgo cardiovascular post-WHI, farmacolog\u00eda de nuevos antagonistas NK3R (fezolinetant, elinzanetant), manejo de menopausia en sobrevivientes de c\u00e1ncer, protocolos de preservaci\u00f3n de fertilidad pre-gonadotoxicidad, y algoritmos basados en medicina de precisi\u00f3n con farmacogen\u00f3mica. | Advanced menopausal management protocols include the post-WHI integrated cardiovascular risk model, pharmacology of novel NK3R antagonists (fezolinetant, elinzanetant), menopause management in cancer survivors, fertility preservation protocols before gonadotoxicity, and precision medicine algorithms with pharmacogenomics.',
      explanation: `## Modelo integrado de riesgo cardiovascular posmenop\u00e1usico | Integrated Postmenopausal Cardiovascular Risk Model

### Efecto del estr\u00f3geno en la aterosclerosis | Estrogen\u2019s Effect on Atherosclerosis
- **Vasos sanos (sin placa)**: Estr\u00f3geno promueve NO, prostaciclina, inhibici\u00f3n de proliferaci\u00f3n de m\u00fasculo liso \u2192 cardioprotector | **Healthy vessels (no plaque)**: Estrogen promotes NO, prostacyclin, smooth muscle proliferation inhibition \u2192 cardioprotective
- **Vasos con aterosclerosis establecida**: Estr\u00f3geno puede desestabilizar placa, activar metaloproteasas, promover trombosis \u2192 da\u00f1ino | **Vessels with established atherosclerosis**: Estrogen can destabilize plaque, activate metalloproteinases, promote thrombosis \u2192 harmful
- Esta dualidad explica la hip\u00f3tesis del timing y los resultados discordantes del WHI | This duality explains the timing hypothesis and discordant WHI results

### Estudios clave de la hip\u00f3tesis del timing | Key Timing Hypothesis Studies
- **ELITE (2016)**: Estradiol oral en <6 a\u00f1os posmenopausia redujo grosor de \u00edntima-media carot\u00eddea vs. >10 a\u00f1os posmenopausia (sin efecto) | **ELITE (2016)**: Oral estradiol in <6 years post-menopause reduced carotid intima-media thickness vs. >10 years post-menopause (no effect)
- **KEEPS (2014)**: ECE oral y estradiol transde\u0301rmico en posmenopausia reciente no afectaron aterosclerosis carot\u00eddea ni calcio coronario | **KEEPS (2014)**: Oral CEE and transdermal estradiol in recent post-menopause did not affect carotid atherosclerosis or coronary calcium
- **Danish Osteoporosis Prevention Study (2012)**: THM temprana redujo mortalidad cardiovascular e infarto sin aumento de c\u00e1ncer a 16 a\u00f1os | **Danish Osteoporosis Prevention Study (2012)**: Early MHT reduced cardiovascular mortality and MI without increased cancer at 16 years

## Farmacolog\u00eda de antagonistas NK3R | NK3R Antagonist Pharmacology

### Fezolinetant | Fezolinetant
- Mecanismo: Antagonista selectivo del receptor de neuroquinina 3 (NK3R) | Mechanism: Selective neurokinin 3 receptor (NK3R) antagonist
- Bloquea neuronas KNDy hiperactivadas \u2192 restaura zona termoneutral | Blocks hyperactivated KNDy neurons \u2192 restores thermoneutral zone
- Dosis: 45 mg VO diario | Dose: 45 mg PO daily
- Ensayos SKYLIGHT 1 & 2: Reducci\u00f3n de frecuencia de bochornos en 60% y severidad en 40% a las 12 semanas | SKYLIGHT 1 & 2 trials: 60% reduction in hot flash frequency and 40% in severity at 12 weeks
- Hepatotoxicidad potencial: ALT/AST pre-tratamiento, a los 3, 6, 9 meses y luego anual | Potential hepatotoxicity: ALT/AST pre-treatment, at 3, 6, 9 months then annually
- Interacci\u00f3n con CYP1A2: Contraindicado con inhibidores fuertes de CYP1A2 (fluvoxamina) | CYP1A2 interaction: Contraindicated with strong CYP1A2 inhibitors (fluvoxamine)

### Elinzanetant (en investigaci\u00f3n) | Elinzanetant (Investigational)
- Antagonista dual NK1R/NK3R | Dual NK1R/NK3R antagonist
- Potencial ventaja: mejora de bochornos Y sue\u00f1o Y estado de \u00e1nimo | Potential advantage: improvement of hot flashes AND sleep AND mood
- Ensayos OASIS 1 & 2: Resultados prometedores | OASIS 1 & 2 trials: Promising results

## Manejo de menopausia en sobrevivientes de c\u00e1ncer | Menopause Management in Cancer Survivors

### C\u00e1ncer de mama (RE+) | Breast Cancer (ER+)
- THM sist\u00e9mica: Contraindicada | Systemic MHT: Contraindicated
- SGM: Lubricantes > estr\u00f3geno vaginal ultra-bajo dosis (solo con aprobaci\u00f3n de oncolog\u00eda) | GSM: Lubricants > ultra-low-dose vaginal estrogen (only with oncology approval)
- Bochornos: Venlafaxina 37.5-75 mg (NO paroxetina ni fluoxetina en pacientes con tamoxifeno \u2013 inhiben CYP2D6) | Hot flashes: Venlafaxine 37.5-75 mg (NOT paroxetine or fluoxetine in patients on tamoxifen \u2013 inhibit CYP2D6)
- Considerar fezolinetant, oxybutinina 2.5 mg noche, gabapentina 300 mg noche | Consider fezolinetant, oxybutynin 2.5 mg at night, gabapentin 300 mg at night
- Salud \u00f3sea: DEXA anual, bisfosfonatos si T-score \u2264 -2.5 o inhibidores de aromatasa | Bone health: Annual DEXA, bisphosphonates if T-score \u2264 -2.5 or on aromatase inhibitors

### Menopausia quir\u00fargica | Surgical Menopause
- Ooforectom\u00eda bilateral causa menopausia abrupta con s\u00edntomas m\u00e1s severos | Bilateral oophorectomy causes abrupt menopause with more severe symptoms
- THM agresiva recomendada si <45 a\u00f1os y no hay contraindicaci\u00f3n | Aggressive MHT recommended if <45 years and no contraindication
- Sin THM: riesgo cardiovascular +17%, mortalidad total +12% (Nurses\u2019 Health Study) | Without MHT: +17% cardiovascular risk, +12% all-cause mortality (Nurses\u2019 Health Study)

## Protocolos de preservaci\u00f3n de fertilidad | Fertility Preservation Protocols

### Pre-gonadotoxicidad (quimioterapia/radioterapia) | Pre-gonadotoxicity (Chemotherapy/Radiation)
- **Criopreservaci\u00f3n de ovocitos/embriones**: Est\u00e1ndar de cuidado si tiempo permite (2 semanas) | **Oocyte/embryo cryopreservation**: Standard of care if time allows (2 weeks)
- **Criopreservaci\u00f3n de tejido ov\u00e1rico**: Para prepuberales o urgencia | **Ovarian tissue cryopreservation**: For prepubertal or urgent cases
- **An\u00e1logos de GnRH**: Leuprolida 3.75 mg IM, comenzando 1-2 semanas antes de quimio | **GnRH analogues**: Leuprolide 3.75 mg IM, starting 1-2 weeks before chemo
  - Metaan\u00e1lisis (POEMS, Del Mastro): Reducci\u00f3n de IOP del 30% al 10-15% | Meta-analysis (POEMS, Del Mastro): POI reduction from 30% to 10-15%

## Farmacogen\u00f3mica aplicada | Applied Pharmacogenomics

### CYP2D6 y tamoxifeno | CYP2D6 and Tamoxifen
- Tamoxifeno se activa a endoxifeno v\u00eda CYP2D6 | Tamoxifen is activated to endoxifen via CYP2D6
- Metabolizadoras lentas (PM): menor eficacia de tamoxifeno | Poor metabolizers (PM): lower tamoxifen efficacy
- **Evitar inhibidores fuertes de CYP2D6**: paroxetina, fluoxetina, bupropion | **Avoid strong CYP2D6 inhibitors**: paroxetine, fluoxetine, bupropion
- **Permitidos**: Venlafaxina, desvenlafaxina, gabapentina | **Permitted**: Venlafaxine, desvenlafaxine, gabapentin`,
      keyTerms: [
        {
          term: 'Antagonista NK3R | NK3R Antagonist',
          definition:
            'Clase farmacol\u00f3gica que bloquea el receptor de neuroquinina 3 en neuronas KNDy para tratar bochornos sin hormonas. | Drug class that blocks neurokinin 3 receptor on KNDy neurons to treat hot flashes without hormones.',
        },
        {
          term: 'Hip\u00f3tesis del timing | Timing Hypothesis',
          definition:
            'Concepto de que el efecto cardiovascular de la THM depende del estado vascular al momento de iniciar: protector si vasos sanos, perjudicial si aterosclerosis avanzada. | Concept that the cardiovascular effect of MHT depends on vascular status at initiation: protective if healthy vessels, harmful if advanced atherosclerosis.',
        },
        {
          term: 'CYP2D6',
          definition:
            'Enzima hep\u00e1tica que activa tamoxifeno a endoxifeno; su inhibici\u00f3n por ciertos medicamentos reduce la eficacia anticancer\u00edgena. | Hepatic enzyme that activates tamoxifen to endoxifen; its inhibition by certain medications reduces anticancer efficacy.',
        },
        {
          term: 'Criopreservaci\u00f3n de tejido ov\u00e1rico | Ovarian Tissue Cryopreservation',
          definition:
            'T\u00e9cnica de preservaci\u00f3n de fertilidad mediante congelaci\u00f3n de corteza ov\u00e1rica para reimplantaci\u00f3n futura. | Fertility preservation technique by freezing ovarian cortex for future reimplantation.',
        },
      ],
      clinicalNotes:
        'La combinaci\u00f3n de estradiol transde\u0301rmico + progesterona micronizada representa el r\u00e9gimen de THM con mejor perfil de seguridad (menor riesgo de TEV, ACV y c\u00e1ncer de mama vs. ECE+MPA oral). Los antagonistas NK3R abren una nueva era en el manejo no hormonal de s\u00edntomas vasomotores. En sobrevivientes de c\u00e1ncer de mama con tamoxifeno, NUNCA prescribir paroxetina o fluoxetina (interacci\u00f3n CYP2D6). | The combination of transdermal estradiol + micronized progesterone represents the MHT regimen with the best safety profile (lower risk of VTE, stroke, and breast cancer vs. oral CEE+MPA). NK3R antagonists open a new era in non-hormonal management of vasomotor symptoms. In breast cancer survivors on tamoxifen, NEVER prescribe paroxetine or fluoxetine (CYP2D6 interaction).',
    },
  },

  media: [],

  citations: [
    {
      id: 'cit-meno-whi',
      type: 'journal',
      title: 'Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women\u2019s Health Initiative',
      authors: ['Manson, J.E.', 'Aragaki, A.K.'],
      source: 'JAMA',
      page: '318(10):927-938',
      accessedDate: '2025-01-10',
    },
    {
      id: 'cit-meno-nams-2022',
      type: 'guideline',
      title: 'The 2022 Hormone Therapy Position Statement of The North American Menopause Society',
      authors: ['North American Menopause Society (NAMS)'],
      source: 'Menopause',
      url: 'https://www.menopause.org/publications/professional-publications',
    },
    {
      id: 'cit-meno-elite',
      type: 'journal',
      title: 'Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE)',
      authors: ['Hodis, H.N.', 'Mack, W.J.'],
      source: 'New England Journal of Medicine',
      page: '374:1221-1231',
    },
    {
      id: 'cit-meno-skylight',
      type: 'journal',
      title: 'Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms (SKYLIGHT 1)',
      authors: ['Johnson, K.A.'],
      source: 'The Lancet',
    },
    {
      id: 'cit-meno-swan',
      type: 'journal',
      title: 'Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition (SWAN)',
      authors: ['Avis, N.E.', 'Crawford, S.L.'],
      source: 'JAMA Internal Medicine',
      page: '175(4):531-539',
    },
    {
      id: 'cit-meno-e3n',
      type: 'journal',
      title: 'Breast Cancer Risk in Relation to Different Types of Hormone Replacement Therapy in the E3N Cohort',
      authors: ['Fournier, A.', 'Berrino, F.', 'Clavel-Chapelon, F.'],
      source: 'International Journal of Cancer',
    },
  ],

  crossReferences: [
    {
      targetId: 'womens-health-ciclo-menstrual-menstrual-cycle',
      targetType: 'process',
      relationship: 'parent',
      label: 'Ciclo menstrual | Menstrual Cycle',
    },
    {
      targetId: 'womens-health-salud-mamaria-breast-health',
      targetType: 'topic',
      relationship: 'related',
      label: 'Salud mamaria | Breast Health',
    },
    {
      targetId: 'womens-health-cancer-ginecologico',
      targetType: 'condition',
      relationship: 'see-also',
      label: 'C\u00e1ncer ginecol\u00f3gico | Gynecologic Cancer',
    },
    {
      targetId: 'osteoporosis-prevention',
      targetType: 'topic',
      relationship: 'related',
      label: 'Prevenci\u00f3n de osteoporosis | Osteoporosis Prevention',
    },
  ],

  tags: {
    systems: ['reproductive', 'endocrine', 'cardiovascular', 'skeletal'],
    topics: ['gynecology', 'endocrinology', 'menopause', 'womens-health', 'hormone-therapy'],
    keywords: [
      'menopausia',
      'menopause',
      'perimenopausia',
      'perimenopause',
      'bochornos',
      'hot flashes',
      'terapia hormonal',
      'hormone therapy',
      'SGM',
      'GSM',
      'osteoporosis',
      'fezolinetant',
      'WHI',
      'insuficiencia ov\u00e1rica primaria',
      'primary ovarian insufficiency',
    ],
    clinicalRelevance: 'high',
    examRelevance: {
      usmle: true,
      nbme: true,
      shelf: ['obstetrics-gynecology', 'medicine'],
    },
  },

  createdAt: '2025-06-01',
  updatedAt: '2025-06-01',
  version: 1,
  status: 'published',
  contributors: ['SOMA Medical Education Team'],
};
